I-Mab Corporate Analyst Meeting Transcript
Good morning or good evening, everyone. Welcome to the 2021 I-Mab Biopharma R&D Day. My name is Jielun Zhu, Chief Financial Officer of I-Mab. I will be your host today.
First, I would like to welcome everyone on behalf of I-Mab. Thank you very much for joining our discussion this morning or this evening. Since 2016, I-Mab has continued to develop into an innovation-driven global biotech company focused on the discovery and development of novel and highly differentiated biologics in immuno-oncology and autoimmune diseases. And now we are well on our way to becoming a biopharma with the near-term commercialization prospect of our first clinical assets.
Now let me introduce the senior management team with me today. We have Dr. Jingwu Zang, Founder and Chairman; Dr. Joan Shen, Chief Executive Officer; and Dr. Taylor Guo, Chief Scientific Officer. They will share with you our overall R&D strategy and the latest progress of I-Mab's key pipeline assets, including some new clinical data we have yet to present before today. For today's event, we
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |